Bibliography
- YUSUF-MAKAGIANSAR H, ANDERSON ME: Inhibition of LFA-1/ ICAM-1 and VLA-4NCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev (2002) 2:146–167.
- •The most recent review of this approach.
- LOBB RR, ADAMS SP: Small molecule antagonists of a4 integrins: novel drugs for asthma. Expert Opin. Investig. Drugs (1999) 8(7):935.
- •Excellent review of this area.
- UN K, ATEEQ HS, HSIUNG SH et al: Selective, tight-binding inhibitors of integrin a4131 that inhibit allergic airway responses. Med. Chem. (1999) 42(5):920–934.
- ABRAHAM WM, GILL A, AHMED A eta].: A small-molecule, tight-binding inhibitor of the integrin a(4)13(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am. I Respir Grit. Care Med. (2000) 162 (2):603–611.
- BAXTER A: GlaxoSmithKline plc: GSK Inaugural Investors Meeting, London — A full and inovative early stage pipeline' Company Presentation. (22 February 2001).
- SPENCE S, VETTER C, HAGMANN WK etal.: Effects of VLA-4 antagonists in rat whole embryo culture. Teratology (2002) 65(1):26–37.
- •Highlights the potential toxicological pitfalls with VLA-4 antagonists.
- MARKHAM RJ: Aventis Pharma AG: FY 2001 analyst conference CompanyPresentation. (13 February 2002).